Inmunoterapia con un extracto de ácaros en niños menores de cinco años

Paniagua, M.J.; Bosque, Montserrat; Asensio, Òscar; Larramona, H.; Marco, Mónica Eva Palacio

doi:10.1016/s0301-0546(02)79082-4

Cited by 9 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were reported in a postmarketing survey that included children <5 years, where 5.6% of patients reported gastrointestinal adverse reactions and oral itching (0.2 adverse effects/1000 doses) . A retrospective study of SCIT in 239 children below the age of 5 years (8–59 months old), who received a total of 6689 injections, reported a single systemic reaction 90 min after an injection in a 3‐year‐old boy . SCIT has also been used to treat 22 toddlers with mite‐allergic asthma (four of whom were less than 3 years old); 7/22 experienced mild bronchospasm as a side‐effect, but continued SCIT . There are reports of the use of VIT in 2‐year‐old patients, but detailed data are missing . Children more than 5 years of age are subjected to the same conditions/contraindications as the adults. No other age group consists a contraindication per se . Conclusion : Allergen immunotherapy is not a treatment option for infants (0–2 years of age).…”

Section: Resultsmentioning

confidence: 99%

Clinical contraindications to allergen immunotherapy: an EAACI position paper

Pitsios

Demoly

Bilò

et al. 2015

Allergy

210

177

View full text Add to dashboard Cite

Clinical indications for allergen immunotherapy (AIT) in respiratory and Hymenoptera venom allergy are well established; however, clinical contraindications to AIT are not always well documented. There are some discrepancies when classifying clinical contraindications for different forms of AIT as 'absolute' or 'relative'. EAACI Task Force on 'Contraindications to AIT' was created to evaluate and review current literature on clinical contraindications, and to update recommendations for both sublingual and subcutaneous AIT for respiratory and venom immunotherapy. An extensive review of the literature was performed on the use of AIT in asthma, autoimmune disorders, malignant neoplasias, cardiovascular diseases, acquired immunodeficiencies and other chronic diseases (including mental disorders), in patients treated with b-blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years of age, during pregnancy and in patients with poor compliance. Each topic was addressed by the following three questions: (1) Are there any negative effects of AIT on this concomitant condition/disease? (2) Are more frequent or more severe AIT-related side-effects expected? and (3) Is AIT expected to be less efficacious? The evidence, for the evaluation of these clinical conditions as contraindications, was limited, and most of the conclusions were based on case reports. Based on an extended literature research, recommendations for each medical condition assessed are provided. The final decision on the administration of AIT should be based on individual evaluation of any medical condition and a risk/benefit assessment for each patient.Allergen immunotherapy (AIT) has been used worldwide for over a century and is currently the only causative therapy for the treatment of respiratory allergies (1-3), and Hymenoptera venom allergy (4). Although clinical indications for AIT are specific and widely accepted, clinical contraindications to AIT differ between various guidelines (1, 2, 4, 5).Allergy 70 (2015) 897-909

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical contraindications to allergen immunotherapy: an EAACI position paper

Pitsios

Demoly

Bilò

et al. 2015

Allergy

210

177

View full text Add to dashboard Cite

show abstract

“…Daten zur Sicherheit und Effektivität der subkutanen Allergen-Immuntherapie im Vorschulalter sind vergleichsweise noch geringer vorhanden. So zeigte eine Studie mit lediglich 22 Kindern im Vorschulalter, die über 17 Monate hinweg bei einem Hausstaubmilben-assoziiertem Asthma eine Therapie erhielten, eine Reduktion der Asthmaexazerbationsrate sowie der Hospitalisationsrate und des Bedarfes an Asthmatherapie [14]. Bei 239 Kleinkindern mit unterschiedlichen allergischen Erkrankungen, die insgesamt 6689 Injektionen erhielten, kam es nur zu einer verzögerten systemischen Reaktion.…”

Section: Allergen-immuntherapie Bei Ersten Krankheitssymptomen (Terti...unclassified

Frühe allergische Sensibilisierung – frühe Allergen-Immuntherapie?

Vogelberg

2024

Kinder- und Jugendmedizin

View full text Add to dashboard Cite

ZUSAMMENFASSUNGAllergische Sensibilisierungen gegen Atemwegsallergene treten häufig bereits im jungen Kleinkindalter auf und bleiben im Verlauf meist bestehen. Damit verbunden ist ein erhöhtes Risiko für die Manifestation eines Asthma bronchiale. Die Allergen-Immuntherapie ist die einzige kausale Therapieform bei Allergien. Für die Anwendung im Kleinkindalter existieren bislang nur wenige Studien, die darauf hinweisen, dass sowohl die sublinguale als auch die subkutane Allergen-Immuntherapie eine sichere Behandlungsform darstellen und Kleinkinder möglicherweise besser auf eine Allergen-Immuntherapie reagieren als andere. Weitere Studien zur Sicherheit, Wirksamkeit, zum präventiven Effekt und zur Toleranz sowie Adhärenz der Allergen-Immuntherapie im Kleinkindalter sind notwendig.

show abstract

Specific Immunotherapy

Pediatric Allergy, Asthma and Immunology

View full text Add to dashboard Cite

Inmunoterapia con un extracto de ácaros en niños menores de cinco años

Abstract: The clinical data if this study suggest that house dust mite specific immunotherapy under hospital control can be begun in young children with good tolerance and clinical improvement.

Cited by 9 publications

References 3 publications

Clinical contraindications to allergen immunotherapy: an EAACI position paper

Clinical contraindications to allergen immunotherapy: an EAACI position paper

Frühe allergische Sensibilisierung – frühe Allergen-Immuntherapie?

Specific Immunotherapy

Contact Info

Product

Resources

About